Pharmacokinetics of Nitazoxanide Dry Suspensions After Single Oral Doses in Healthy Subjects: Food Effects Evaluation and Bioequivalence Study

Abstract

AbstractNitazoxanide (NTZ) is an effective antiparasitic drug with potent antiviral and antimicrobial activity. This randomized, open‐label, 2‐sequence, 2‐period crossover trial was designed to evaluate the bioequivalence (BE) of the NTZ dry suspension in healthy subjects and investigated the effect of food intake on the pharmacokinetic (PK) properties of tizoxanide (an active metabolite of NTZ, TIZ). Sixty healthy Chinese subjects were enrolled and received a single dose of 500 mg/25 mL of preparations on days 1 and 4 under overnight fasting or fed conditions, respectively. The plasma concentration of TIZ was determined using high‐performance liquid chromatography/tandem mass spectrometry. PK parameters were calculated using WinNonlin 8.2 and BE was evaluated using SAS 9.4. The 90% confidence intervals for the geometric mean ratio (test/reference) of maximum concentration (Cmax), the area under the curve from time 0 to the time of the last quantifiable concentration (AUC0‐t), and the area under the curve from time 0 to extrapolation to infinity (AUC0‐∞) were all within the equivalent interval of 80%‐125%, compliant with BE requirements. In comparison with fasting, on taking the reference and test preparations of the NTZ dry suspension after a meal, the AUC0‐t increased by 48.9% and 47.3%, respectively, the AUC0‐∞ increased by 48.4% and 48.3%, respectively, and the post‐meal Tmax was prolonged by 1.8‐2 hours. Our results demonstrate that the test and reference preparations were bioequivalent. High‐fat meals significantly improve the degree of drug absorption and delay the rate of drug absorption.